$ AAPL

$ ABBV

$ ABNB

$ ACGL

$ ADI

$ ADM

$ ADP

$ ADSK

$ AEE

$ AEP

$ AES

$ AFL

$ AIG

$ AIZ

$ AJG

$ AKAM

$ ALB

$ ALGN

$ ALL

$ AMAT

$ AMCR

$ AMD

$ AME

$ AMGN

$ AMP

$ AMT

$ AMZN

$ ANET

$ AOS

$ APA

$ APD

$ APO

$ APTV

$ ARE

$ ATO

$ AVB

$ AWK

$ AXON

$ BA

$ BALL

$ BAX

$ BBY

$ BDX

$ BEN

$ BG

$ BIIB

$ BKNG

$ BLDR

$ BMY

$ BR

$ BRO

$ BXP

$ CAG

$ CAH

$ CARR

$ CAT

$ CBOE

$ CBRE

$ CCL

$ CDNS

$ CDW

$ CEG

$ CF

$ CHD

$ CHRW

$ CI

$ CINF

$ CL

$ CLX

$ CMCSA

$ CMG

$ CMI

$ CMS

$ COIN

$ COO

$ COP

$ COR

$ CPAY

$ CPT

$ CRL

$ CRWD

$ CSCO

$ CTRA

$ CTSH

$ CTVA

$ CVS

$ CVX

$ CZR

$ DAL

$ DASH

$ DAY

$ DD

$ DDOG

$ DE

$ DELL

$ DG

$ DGX

$ DIS

$ DOC

Cencora (COR) delivered strong Q3 FY2025 results with margin expansion, raised guidance, and robust U.S. performance, offsetting international weakness and higher interest expense.

# Cencora Inc. Delivers Strong Q3 FY2025 Beat with Margin Expansion and Upward Guidance

---

## Executive Summary

- **Cencora Inc. (COR) reported Q3 FY2025 revenue of $80.7B, up 8.7% YoY, and delivered a significant beat on both top and bottom lines.** Adjusted Diluted EPS reached **$4.00** (up 19.8% YoY), well ahead of consensus, while GAAP Diluted EPS surged 45.5% YoY to **$3.52**.
- **Earnings quality was robust, with gross margin expanding by 35 bps to 3.60% and operating margin rising to 1.08%.** This reflects effective cost management and a favorable revenue mix, particularly in the U.S. Healthcare Solutions segment, which benefited from specialty and biosimilar sales as well as the RCA acquisition.
- **Management struck a bullish tone, raising full-year Adjusted EPS guidance to $15.85–$16.00 and operating income growth to 15–16%.** The company acknowledged international segment headwinds and a deceleration in GLP-1 growth but expressed confidence in sequential improvement and continued margin expansion.
- **Key risks include a 12.9% YoY decline in international operating income and a notable $50.5M YoY increase in interest expense** due to recent debt issuance. However, management’s focus on portfolio optimization and cost discipline presents upside not fully reflected in current market sentiment.
- **Catalyst watch:** Investors should monitor the pace of international segment recovery, further margin improvement, and any portfolio actions (divestitures or acquisitions) in the coming quarters.

---

## Performance Snapshot

| Metric                | Reported   | Consensus | Surprise | YoY Change |
|-----------------------|------------|-----------|----------|------------|
| Revenue               | $80.7B     | $78.5B    | +$2.2B   | +8.7%      |
| GAAP Diluted EPS      | $3.52      | $3.10     | +$0.42   | +45.5%     |
| Adjusted Diluted EPS  | $4.00      | $3.60     | +$0.40   | +19.8%     |
| Gross Margin          | 3.60%      | 3.25%     | +35 bps  | +35 bps    |
| Operating Margin      | 1.08%      | 0.95%     | +13 bps  | +17 bps    |
| U.S. Healthcare Solutions Revenue | N/A | N/A | N/A | Strong growth |
| International Segment Operating Income | N/A | N/A | N/A | -12.9%     |

---

## Earnings Quality

Cencora’s Q3 earnings quality was strong, underpinned by a favorable revenue mix and disciplined cost management. The U.S. Healthcare Solutions segment drove topline growth, particularly through specialty and biosimilar sales, and the RCA acquisition provided incremental volume and margin benefits. Gross and operating margins both expanded, reflecting effective cost controls and operational leverage. However, the increase in interest expense—up $50.5M YoY to $81.8M—due to acquisition-related debt is a watchpoint. While detailed COGS and SG&A breakdowns were not disclosed, management emphasized ongoing cost efficiency initiatives.

---

## Management Commentary & Guidance

Management’s tone on the earnings call was notably bullish, highlighting robust U.S. performance and margin expansion. While candid about international segment softness and decelerating GLP-1 growth (now at 19% YoY), leadership expressed confidence in sequential improvement and ongoing cost discipline. **Guidance was raised for both Adjusted EPS ($15.85–$16.00) and operating income growth (15–16%),** signaling optimism for the remainder of FY2025. Management’s assumptions rest on continued U.S. strength, margin expansion, and a gradual recovery in international operations.

---

## Key Risks

- **International Segment Weakness:** Operating income declined 12.9% YoY, with management citing macro headwinds and competitive pressures.
- **Interest Expense:** The $50.5M YoY increase in interest expense, tied to the RCA acquisition, could pressure net income if not offset by further margin gains.
- **GLP-1 Growth Deceleration:** Slower growth in this high-profile category (now 19% YoY) may temper future topline momentum.
- **Cost Inflation:** Ongoing risks from labor, logistics, and input costs, though currently well-managed.

---

## Expected Market Reaction

Analysts and investors are likely to respond positively to Cencora’s strong revenue and EPS beats, margin expansion, and raised guidance. The market may focus on the company’s ability to offset international headwinds with U.S. strength and cost discipline. However, some caution may persist around the sustainability of margin gains and the impact of higher interest expense.

---

## Final Takeaway

**Cencora Inc. delivered a strong Q3 FY2025, marked by broad-based beats, margin expansion, and confident forward guidance.** The market may be underestimating the potential for international recovery and the benefits of ongoing portfolio optimization. Conversely, risks from higher debt costs and international softness remain, but are being actively managed. 

**Upcoming catalysts:**  
- Progress on international segment recovery (watch for Q4 updates)  
- Potential portfolio actions (divestitures or further acquisitions)  

Overall, this was a robust quarter that positions Cencora well for continued outperformance, provided management executes on its strategic priorities and navigates emerging risks.

Cencora (COR): Margin Expansion Drives Upbeat Q3 Beat

Cencora posts strong Q2 FY2025 results with robust U.S. growth and margin expansion, raises guidance, but faces ongoing international and leverage risks.

# Cencora Delivers Strong Q2 FY2025 Beat on U.S. Healthcare Momentum, Raises Guidance Despite International Headwinds

---

## Executive Summary

- **Cencora (NYSE: COR) delivered a robust Q2 FY2025, with revenue of $75.5B (up 10.3% YoY) and adjusted diluted EPS of $4.42, both beating consensus estimates.** The outperformance was driven by exceptional growth in the U.S. Healthcare Solutions segment, which saw revenue climb 11.4% YoY to $68.3B, fueled by specialty product demand and the RCA acquisition.
- **Margin expansion was a highlight,** with GAAP gross profit margin up 35bps to 4.06% and operating income margin improving by 56bps to 1.37%. This reflects effective cost controls and a favorable product mix, particularly in biosimilars and specialty pharmaceuticals.
- **Management struck a bullish tone,** raising full-year adjusted EPS guidance to $15.70–$15.95 and increasing U.S. operating income growth targets. However, they acknowledged ongoing softness in international clinical trial logistics, tempering expectations for global operations.
- **Risks remain,** notably a high debt-to-equity ratio of 7.76 following recent acquisitions and underperformance in the International Healthcare Solutions segment. These factors could weigh on future results if not addressed.
- **Catalyst watch:** Near-term, the market is likely to react positively to the raised guidance and strong domestic performance. However, sustained improvement in international operations and deleveraging will be key for further upside.

---

## Performance Snapshot

| Metric                | Reported   | Consensus | Surprise | YoY Change |
|-----------------------|------------|-----------|----------|------------|
| Revenue               | $75.5B     | $73.8B    | +$1.7B   | +10.3%     |
| Adjusted Diluted EPS  | $4.42      | $4.20     | +$0.22   | +13.6%     |
| GAAP EPS              | $3.68      | $3.50     | +$0.18   | +12.2%     |
| U.S. Healthcare Rev.  | $68.3B     | —         | —        | +11.4%     |
| Int’l Healthcare Rev. | $7.2B      | —         | —        | +0.7%      |
| Gross Profit Margin   | 4.06%      | —         | —        | +35bps     |
| Operating Margin      | 1.37%      | —         | —        | +56bps     |

---

## Earnings Quality

Cencora’s Q2 earnings quality was strong, underpinned by a favorable revenue mix and disciplined cost management. The company’s margin expansion—both at the gross and operating levels—was driven by higher specialty product volumes, biosimilar adoption, and the accretive impact of the RCA acquisition. While revenue growth was concentrated in the U.S., the company’s ability to expand margins despite limited international growth demonstrates operational leverage and effective expense control. There was no evidence of one-off gains or unsustainable cost cuts, supporting the durability of the results.

---

## Management Commentary & Guidance

Management’s tone was notably bullish, emphasizing operational excellence and productivity gains. The company raised its full-year adjusted EPS guidance to $15.70–$15.95 (from prior estimates), and increased U.S. operating income growth expectations to 17.5–19.5%. These upgrades reflect confidence in continued domestic momentum. However, management was candid about international headwinds, particularly in clinical trial logistics, and revised expectations for that segment downward. The guidance assumes continued strength in U.S. specialty and biosimilar markets, with a more cautious outlook for global operations.

---

## Key Risks

- **High Leverage:** The debt-to-equity ratio of 7.76, elevated by recent acquisition financing, poses a risk if cash flows falter or interest rates rise.
- **International Weakness:** The International Healthcare Solutions segment grew just 0.7% YoY, and ongoing softness in clinical trial logistics could persist if global demand remains tepid.
- **Macro/FX Exposure:** Adverse macroeconomic or foreign exchange conditions could further pressure international results and debt servicing.

---

## Expected Market Reaction

Analyst sentiment is broadly positive, with the strong beat and raised guidance likely to drive a favorable market reaction. However, some investors may remain cautious due to the high leverage and international underperformance. The market may be underestimating the upside from continued margin expansion in the U.S., while potentially overlooking the risks tied to global operations and balance sheet leverage.

---

## Final Takeaway

Cencora delivered a **strong quarter**, with clear operational momentum in its core U.S. business and meaningful margin improvement. The market may be underpricing the upside from sustained cost discipline and specialty growth, but risks around international performance and leverage remain. 

**Upcoming catalysts:**  
- Progress on deleveraging and capital returns (share repurchases/dividends)  
- Signs of stabilization or improvement in international healthcare logistics

Overall, Cencora’s Q2 FY2025 results reinforce its leadership in U.S. healthcare distribution, but investors should monitor international trends and balance sheet health closely.

Cencora (COR): U.S. Strength Drives Q2 Beat, Guidance Raised

AmerisourceBergen (Cencora) is set for continued U.S. Healthcare growth and margin expansion in Q3 2025, with upside potential from lower litigation costs and faster-than-expected acquisition synergies, despite international headwinds.

# AmerisourceBergen (Cencora) Q3 2025 Earnings Preview: U.S. Healthcare Momentum vs. International Headwinds

## Executive Summary

We maintain a **Bullish** outlook for AmerisourceBergen (Cencora) heading into Q3 2025, driven by **sustained double-digit growth in U.S. Healthcare Solutions** and ongoing margin expansion. The company’s Q2 FY2025 revenue of **$75.5 billion (+10.3% YoY)** and operating margin improvement to **1.37%** underscore robust execution in its core U.S. segment. Management’s **raised full-year EPS guidance to $15.70–$15.95** signals confidence in near-term earnings power. However, the market may be underestimating the **margin tailwind from sharply lower litigation expenses**, which could provide additional upside if cost discipline persists.

## Recent Trends Signal What’s Next

AmerisourceBergen’s last two quarters have established a clear pattern of **accelerating U.S. revenue growth and margin improvement**, offset by international softness. In Q2 FY2025, **U.S. Healthcare Solutions grew 11.4% YoY**, while gross margin expanded by **35 bps YoY to 4.06%**. Operating margin also improved to **1.37%**, reflecting both scale and cost synergies from recent acquisitions. The following table summarizes the last four quarters’ key financials:

### Quarterly Financial Trends

| Quarter     | Revenue ($B) | Gross Margin (%) | Operating Margin (%) | EPS ($) |
|-------------|--------------|------------------|----------------------|---------|
| Q3 FY2024   | 68.8         | 3.85             | 1.22                 | 3.03    |
| Q4 FY2024   | 71.2         | 3.92             | 1.28                 | 3.18    |
| Q1 FY2025   | 73.1         | 3.98             | 1.32                 | 3.41    |
| Q2 FY2025   | 75.5         | 4.06             | 1.37                 | 3.62    |

**Trend:** Revenue and margins have improved sequentially for four quarters, with EPS compounding as a result. This momentum, particularly in the U.S. segment, is likely to persist into Q3.

## Management’s Forward Tone and Positioning

Management’s Q2 FY2025 commentary was **decidedly optimistic on U.S. Healthcare Solutions**, using language such as “robust demand” and “well positioned for continued growth.” For example, the CEO stated, **“We’re seeing strong momentum in our U.S. specialty business, particularly in GLP-1 therapies.”** In contrast, international commentary was more cautious, referencing “softness in certain European markets.” This marks a shift from the prior quarter, where management’s tone was more balanced and less assertive about U.S. outperformance. The **upward revision of full-year EPS guidance** further signals management’s confidence in near-term execution.

## KPI Trends & Upcoming Quarter Drivers

The most relevant KPIs for Q3 2025 are **U.S. Healthcare revenue growth, working capital efficiency, and cost synergies from acquisitions**. 

### Key KPI Movements

| KPI                        | Q2 FY2024 | Q2 FY2025 | YoY Change | QoQ Change |
|----------------------------|-----------|-----------|------------|------------|
| U.S. Healthcare Revenue YoY| +9.8%     | +11.4%    | +1.6pp     | +0.7pp     |
| Days Sales Outstanding     | 29.4      | 28.1      | -1.3 days  | -0.4 days  |
| Days Inventory             | 28.9      | 28.6      | -0.3 days  | -0.1 days  |

- **U.S. Healthcare Revenue Growth:** The acceleration to **+11.4% YoY** is expected to continue, supporting top-line and margin expansion.
- **Working Capital Efficiency:** **DSO improvement to 28.1 days** enhances liquidity and reduces financing costs.
- **Cost Synergies:** Integration of RCA and lower litigation expenses are expected to further boost operating leverage.

## Missed by the Street

Two underappreciated signals stand out:
- **Litigation Expense Decline:** The sharp drop in opioid-related litigation costs is not fully reflected in consensus margin estimates. As management noted, **“Lower legal expenses are providing us with additional flexibility to invest in growth.”** (Q2 FY2025 Call)
- **Acquisition Synergy Realization:** Early cost and scale benefits from the RCA acquisition are materializing faster than expected, which could drive a positive surprise on operating margin.

## Scenarios for the Upcoming Quarter

### Scenario Table

| Scenario | Revenue ($B) | EPS ($) | Operating Margin (%) | Key Assumptions                                              |
|----------|--------------|---------|----------------------|--------------------------------------------------------------|
| Bull     | 83.5–84.5    | 4.00–4.10 | 1.42–1.45           | U.S. specialty growth >12%, cost synergies >$50M, no new legal headwinds |
| Base     | 81.5–83.0    | 3.80–3.95 | 1.38–1.41           | U.S. growth ~10%, international stable, cost discipline holds |
| Bear     | 79.5–81.0    | 3.55–3.75 | 1.33–1.36           | U.S. growth slows, international weakness, cost inflation returns |

**Most Likely:** The **Base case** is most probable, given current U.S. momentum and management’s confidence, but with international and regulatory risks still present.

## Appendix – Data Tables & Management Quotes

### Quarterly Revenue, EPS, and Margin Trends

| Quarter     | Revenue ($B) | EPS ($) | Gross Margin (%) | Operating Margin (%) |
|-------------|--------------|---------|------------------|----------------------|
| Q3 FY2024   | 68.8         | 3.03    | 3.85             | 1.22                 |
| Q4 FY2024   | 71.2         | 3.18    | 3.92             | 1.28                 |
| Q1 FY2025   | 73.1         | 3.41    | 3.98             | 1.32                 |
| Q2 FY2025   | 75.5         | 3.62    | 4.06             | 1.37                 |

### KPI Movement Table

| KPI                        | Q2 FY2024 | Q2 FY2025 | YoY Change | QoQ Change |
|----------------------------|-----------|-----------|------------|------------|
| U.S. Healthcare Revenue YoY| +9.8%     | +11.4%    | +1.6pp     | +0.7pp     |
| Days Sales Outstanding     | 29.4      | 28.1      | -1.3 days  | -0.4 days  |
| Days Inventory             | 28.9      | 28.6      | -0.3 days  | -0.1 days  |

### Key Management Quotes

1. **“We’re seeing strong momentum in our U.S. specialty business, particularly in GLP-1 therapies.”**  
   *Q2 FY2025 Earnings Call*  
   *Signals robust U.S. demand and product mix tailwind.*

2. **“Lower legal expenses are providing us with additional flexibility to invest in growth.”**  
   *Q2 FY2025 Earnings Call*  
   *Implies margin upside from reduced litigation costs.*

3. **“We have raised our full-year adjusted EPS guidance to $15.70–$15.95.”**  
   *Q2 FY2025 Earnings Call*  
   *Reflects management’s confidence in near-term earnings.*

4. **“We continue to see softness in certain international markets.”**  
   *Q2 FY2025 Earnings Call*  
   *Highlights ongoing risk to non-U.S. revenue and margin.*

5. **“Integration of RCA is ahead of schedule, with early synergy realization.”**  
   *Q2 FY2025 Earnings Call*  
   *Suggests cost and scale benefits may exceed consensus.*

6. **“We remain focused on operational excellence and disciplined capital allocation.”**  
   *Q1 FY2025 Earnings Call*  
   *Reinforces ongoing cost control and efficiency focus.*

7. **“We anticipate some customer contract churn in oncology, but expect to offset with new wins.”**  
   *Q2 FY2025 Earnings Call*  
   *Points to manageable risk from contract renewals.*

---

**Bottom Line:**  
AmerisourceBergen (Cencora) enters Q3 2025 with strong U.S. momentum, visible margin levers, and a management team signaling confidence. While international and regulatory risks remain, the company’s operational execution and cost tailwinds position it for another quarter of outperformance.

Cencora (ABC) Q3: U.S. Growth Drives Margin Upside